Patenting Antibodies at the European Patent Office

In the recent issue of International Biopharmaceutical Journal, our client examines the breadth of claims that might be obtained in different circumstances based on current European Patent Office practice, and considers when questions of lack of enablement are most likely to arise in an antibody case.